ASSESSMENT OF DIRECT RESULTS OF CERVICAL CANCER COMBINED TREATMENT

The aim of the study was to evaluate the immediate results of combined treatment of cervical cancer. This study included 177 patients with cervical cancer. The mean age of patients was 48.0±1.9 years. According to stages the patients were divided as follow: IIA - 56 patients, IIB - 67, III - 54 patients. All patients with cervical cancer are divided into 3 groups: one control and two investigative. Patients of the control group (55 people) received only radiotherapy (RT). The investigative group 1 of 77 patients received RT in combination with ftorafur per os at a dose of 1200 mg in days of EBRT (800 mg in the morning and 400 mg in the evening) No. 23, total dose of 27,600 mg. The investigative group 2 included 45 patients in whom RT was performed in combination with cisplatin at a dose of 40 mg/m2 every 7 days during the entire course of radiation therapy. The effectiveness of combined treatment was assessed according to standard WHO criteria (1978). The combination of radiotherapy with cisplatin allowed to increase the incidence of complete and clinical responses of the cervical tumor by 28.3% compared with only radiation therapy, and also, statistically significant increase in the degree of regression of cervical cancer to 26.7% compared with patients of the control group and to 24.1% compared with patients receiving combination therapy with ftorafur. The most pronounced hematological toxicity was observed in patients with cervical cancer who received SLT with cisplatin, which did not require interruption of radiation treatment and reduction of chemotherapy dosages, the lowest hematological toxicity was in patients receiving radiation therapy alone.